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Introduction
============

An adverse outcome pathway (AOP) is the process by which a chemical causes an adverse outcome in a tissue starting with an interaction with a molecular target (termed the molecular initiating event (MIE)), through a number of key molecular and cellular events ([@r3]; [@r34]; [@r45]). A subset of AOPs that lead to liver cancer involve the chronic activation of xenobiotic-activated receptors that regulate growth of the liver. The MIE of one of these AOPs is the activation of the nuclear receptor constitutive activated receptor (CAR, NR1I3) ([@r14]). CAR plays critical roles in regulating enzymes involved in xenobiotic metabolism, including members of the cytochrome P450 (CYP) family ([@r43]), sulfotransferases, uridine diphospho-glucuronosyltransferases ([@r8]; [@r41]), as well as various transporters ([@r4]). Heterodimers of CAR and the retinoid X receptor (RXR, NR2B1) bind to phenobarbital-responsive elements in chromatin, resulting in gene activation. CAR can be activated through two distinct mechanisms. A number of compounds (e.g., 1,4-bis-\[2-(3,5-dichloropyridyloxy)\] benzene (TCPOBOP), and 6-(4-chlorophenyl)imidazo\[2,1-b\]\[1,3\]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime (CITCO)) bind directly to CAR, leading to nuclear localization and transcriptional activation. In contrast, phenobarbital activates CAR by binding to and inactivating the epidermal growth factor receptor (EGFR) and an associated protein kinase cascade that in the absence of exposure, suppresses CAR nuclear translocation ([@r29]; [@r26]). The ability of CAR to respond to environmentally-relevant chemicals allows CAR, in concert with other transcription factors (e.g., pregnane X receptor (PXR, NR1I2) and aryl hydrocarbon receptor (AhR)), to induce gene expression of enzymes and transporters that metabolize and remove potentially toxic xenobiotics from the liver.

Many activators of rodent CAR, including phenobarbital, are well known inducers of liver cancer in mice and rats. The CAR-dependent liver cancer AOP has been recently reevaluated ([@r14]), building on previous efforts (e.g., [@r19]). Sustained CAR activation (the MIE) is followed by a number of key events including alteration of the expression of genes involved in hepatocyte fate, increased hepatocyte proliferation, formation of altered hepatic foci and ultimately, the development of hepatocellular adenomas and carcinomas. Induction of hepatic *CYP2B* gene expression and enzymes has been used as a surrogate indicator of CAR activation ([@r14]). Many of the most important studies used to support the AOP stem from work comparing effects in wild-type and CAR-null mice in which both short- and long-term exposures to CAR activators were shown to be CAR-dependent, including phenobarbital- or TCPOBOP-induced liver cancer ([@r20]; [@r47]). Although the CAR AOP is well established for phenobarbital and TCPOBOP, other CAR-activating chemicals that induce liver cancer have not been systematically evaluated by a weight of evidence approach for causing liver cancer through the CAR AOP ([@r14]).

Recent studies have expanded the biological and pathophysiological functions of CAR to include cross-talk with regulators of liver energy homeostasis that impact metabolic diseases ([@r22]; [@r16]). In models of diabetes (high fat diet or leptin-deficient mice (*ob/ob*)), activation of CAR significantly reduces serum glucose levels and improves glucose tolerance and insulin sensitivity through suppression of glucose production and stimulation of glucose uptake and metabolism in the liver ([@r13]; [@r15]). While activation of CAR results in a more favorable metabolic profile, suppression of CAR (i.e., in CAR-null mice) led to spontaneously-impaired insulin sensitivity that was not responsive to TCPOBOP ([@r15]). Loss of CAR resulted in increased hepatic triglyceride accumulation that was associated with increased expression of the lipogenic nuclear receptor liver X receptor (LXR) and target genes including the sterol regulatory element binding protein 1 (SREBP-1). Activation of CAR inhibited the expression of LXR target genes and LXR ligand-induced lipogenesis ([@r48]). Therefore, a hypothesized AOP that leads to liver triglyceride accumulation associated with insulin insensitivity involves suppression of CAR as the MIE, loss of negative regulation of LXR, and indirect activation of LXR- and SREBP-1-dependent lipogenic genes ([@r21]).

The ability to accurately predict CAR activation or suppression would help in evaluating the potential for chemicals and other factors to contribute to liver cancer or metabolic derangements through this nuclear receptor. In the present study, a gene expression biomarker signature coupled with a rank-based similarity test was used to predict CAR activation or suppression. The biomarker signature was found to be very accurate in predicting the activation of CAR and was used to screen a compendium of gene expression profiles to find chemicals that modulate CAR.

Materials and Methods
=====================

Strategy for identification of chemicals that affect CAR.
---------------------------------------------------------

The methods used in the present study are outlined in [Figure 1](#f1){ref-type="fig"}. The methods used are similar to those described previously ([@r31]).

![CAR biomarker signature development/characterization and screening of a mouse liver gene expression compendium.\
Left, biomarker signature development and characterization. Wild-type and CAR-null mice were treated with CITCO, phenobarbital (PB) or TCPOBOP ([@r10]) and microarray analysis was carried out on the livers. Rosetta Resolver was used to identify differentially expressed genes (DEGs), as indicated. Biomarker signature genes were identified from the DEGs after applying a number of filtering steps described in the Methods. Genes in the biomarker signature were evaluated by the Comparative Toxicogenomics Database (CTD) to evaluate literature evidence for consistent regulation of biomarker signature genes by CAR activators and by Ingenuity Pathway Analysis (IPA) for canonical pathway enrichment and potential transcription factor (TF) regulators. Right, biomarker signature testing and screening. The CAR biomarker signature was imported into the NextBio environment. Internal protocols rank ordered the genes based on their fold-change. A pair-wise rank-based enrichment analysis (the Running Fisher's algorithm) was used to compare the CAR biomarker signature to each bioset in the NextBio database, resulting in the direction of correlation and p-value of the comparison for each bioset in the compendium. All comparison information was exported and used to populate a master table containing bioset experimental details. An accuracy test of the biomarker signature predictions was carried out with treatments that are known positives and negatives for CAR activation. A number of predictions were tested in independent studies based on screening "hits". An external gene expression database of experiments using Affymetrix gene chips was used for the machine learning classification analysis by BRB Array Tools. The database was also used to assess the relationship between the Running Fisher's algorithm p-value and behavior of the CAR biomarker signature genes. Parts of the figure were adapted from a figure in [@r23] and [@r31].](nrs-13-002-g1){#f1}

Animal studies.
---------------

There were a total of 4 animal studies carried out as part of this investigation. The studies of PFNA and PFHxS in wild-type and PPARα-null mice, pregnenolone-16-α-carbonitrile (PCN) in wild-type and *Pxr*-null mice and the 12-treatment study in male and female mice have been described previously ([@r31]).

Perfluorooctanoic acid, perfluorooctane sulfonate, propiconazole, and triadimefon in wild-type and CAR-null mice: this study was carried out at the University of Kansas Medical Center (Kansas City, KS) in a fully-accredited American Association for Accreditation of Laboratory Animal Care facility. The animal study was conducted under federal guidelines for the use and care of laboratory animals and was approved by KUMC Institutional Animal Care and Use Committees. Breeder pairs from the CAR-null mouse line on the C57BL/6 background were obtained from Dr. Ivan Rusyn (University of North Carolina, Chapel Hill, NC) that were engineered by Tularik, Inc. (South San Francisco, CA), as described previously ([@r43]). Randomized animals were allowed to acclimate for a period of one week prior to conducting the study. Food (Purina Rodent Chow (Harlan Teklad 8604) and filtered distilled water were provided ad libitum. Animal facilities were controlled for temperature (20-24°C), relative humidity (40-60%), and kept under a 12 hr light-dark cycle. Wild-type and CAR-null mice were given perfluorooctanoic acid (3 mg/kg), perfluorooctane sulfonate (3 mg/kg), propiconazole (210 mg/kg), or triadimefon (165 mg/kg) each day by gavage for 7 days. Control mice received 7.5% alkamuls by gavage. Livers were removed 24-hrs after the last dose. Portions of the livers were rapidly snap-frozen in liquid nitrogen and stored at -70°C until analysis. All animal studies were conducted under federal guidelines for the use and care of laboratory animals and were approved by Institutional Animal Care and Use Committees.

Evaluation of cell proliferation.
---------------------------------

Cell proliferation by Ki67 immunohistochemical staining was determined in the livers from mice treated with PFOA and propiconazole (Study 4) by Experimental Pathology Laboratories, Inc., Durham, NC. Tissue samples in paraffin blocks were sectioned, deparaffinized and hydrated. Samples were incubated in 1:20 citrate buffer for 7 min under pressure (decloaking) and then cooled. Blocking steps included quenching of endogenous peroxides with 3% H~2~O~2~, an avidin block, a biotin block and incubation with blocking serum. Sections were labeled with rat anti-mouse Ki67 antibody (1:25 dilution) and a rabbit anti-rat IgG secondary antibody (1:300). Slides were developed using an avidin-biotin complex method following an application of 3,3′-diaminobenzidine as the chromogen ([@r28]). The percent labeling indices (LI) were determined by counting the number of positively-stained Ki67 nuclei in 900-1400 hepatocyte nuclei/animal from photographic images taken at 40X. Each image was scored and analyzed for accuracy.

Classification analysis using machine learning methods.
-------------------------------------------------------

Analyses were performed using BRB-ArrayTools version 4.2.1 Stable Release developed by Dr. Richard Simon and BRB-ArrayTools Development Team (<http://linus.nci.nih.gov/BRB-ArrayTools.html>) ([@r39]). These studies were carried out independently of the use of the CAR biomarker signature described below. The procedures used were similar to those described previously ([@r31]). "All samples used in the training and testing sets were first log2 normalized using RMA in the RMAExpress software environment (<http://rmaexpress.bmbolstad.com/>). The cel files from the three Affymetrix array types (mouse 430A, mouse 430_2 and mouse 430PM arrays) were normalized separately. Normalized expression values of common probesets (22,626) were then combined into one master file. Prior to classification, probesets were excluded under any of the following conditions: 1) minimum fold change - less than 20% of the expression data values have at least a 1.5-fold change in either direction from the median value of the genes, 2) variance is in the bottom 75^th^ percentile, or 3) percent missing exceeds 50%. Filtering using these criteria resulted in 5644 probesets used in the classification study. The 7 models used for class prediction included Compound Covariate Predictor, Bayesian Compound Covariate, Diagonal Linear Discriminant Analysis, 1- and 3-Nearest Neighbor Classifications, Nearest Centroid, and Support Vector Machines with Linear Kernel. The models incorporated genes that were differentially expressed at p ≤ 0.001 significance level, as assessed by the random variance t-test. The prediction error of each model was estimated using 10-fold cross-validation." Two training sets were used for predicting CAR activation: the samples from wild-type and CAR-null mice from [@r10] and the same dataset lacking the control and treated CAR-null samples. The derived classifiers of 110 or 247 probesets, respectively, were then used to predict CAR activation of the remaining samples. A test set of 80 and 239 samples known to be positive or negative, respectively, for CAR activation came from a number of studies in which mice or mouse primary hepatocytes were exposed to CAR activators or control substances ([@r17]; [@r38]; Study 1 and Study 3 (above)).

Construction of a CAR-dependent biomarker signature.
----------------------------------------------------

The general strategy for biomarker signature development is outlined in [Figure 1](#f1){ref-type="fig"}, left. A list of probe sets that comprise the CAR biomarker signature was derived using livers of wild-type and CAR-null mice treated with CITCO, phenobarbital, or TCPOBOP for 3 days ([@r10]). Three statistical tests were used for each chemical: 1) chemical-treated wild-type vs. wild-type control; 2) chemical-treated CAR-null vs. CAR-null controls; and 3) chemical-treated wild-type vs. chemical-treated CAR-null. For each chemical, genes were identified which exhibited differences in expression in wild-type mice, but no statistically significant expression in the same direction in the CAR-null mice. This list of genes was then examined for statistical differences between the treated wild-type mice and the treated CAR-null mice. The three lists of genes (one for each chemical) were compared and probe sets were selected based on the following criteria: 1) probe sets were altered in at least 2 or 3 out of the 3 comparisons, 2) probe sets exhibited the same direction of change after exposure to all chemicals, 3) probe sets that encoded the same gene had identical direction of change after exposure, 4) the \|average fold change\| for each probe set was ≥ 1.5-fold, and 5) the probe sets were not also altered in the same direction in gene expression biomarker signatures for AhR, PPARα, Nrf2, and STAT5b ([@r31] and in preparation). These criteria for selection ensured that the probe sets exhibited absolute dependence on CAR, a robust response, and consistent chemical-independent regulation. The final list of probesets in the CAR biomarker signature is found in [Supplementary File 1](#SM1){ref-type="supplementary-material"}.

Additional methods.
-------------------

All additional methods used in this study have been previously described in [@r31], including RNA isolation, microarray analyses, identification of differentially expressed genes in microarray datasets, functional analyses of the signature genes, assembly of an annotated mouse liver gene expression compendium, evaluation of activation using the Running Fisher's algorithm, tissues used for RT-PCR analysis and RT-PCR.

Results
=======

Development and analysis of the CAR biomarker signature
-------------------------------------------------------

CAR biomarker genes were identified as described in the Methods using profiles from the livers of wild-type and CAR-null mice treated with phenobarbital, TCPOBOP or CITCO for 3 days ([@r10]) ([Figure 1](#f1){ref-type="fig"}). A total of 128 probe sets (120 with increased expression and 8 with decreased expression, collapsing to 83 genes) were identified which exhibited similar regulation by two or three out of the three compounds. The full list of genes is found in [Supplementary File 1](#SM1){ref-type="supplementary-material"}. [Figure 2A](#f2){ref-type="fig"} shows the dependence of chemical-induced changes in expression on CAR when comparing treated wild-type and CAR-null mice for the three chemicals.

![Characterization of the CAR biomarker signature.\
A. Expression behavior of genes in the signature. The heat map shows the expression of the 128 probe sets after exposure to CITCO, phenobarbital (PB), and TCPOBOP in wild-type and CAR-null mice compared to the final signature. B. Expression behavior of the CAR signature genes in the Comparative Toxicogenomics Database (CTD). The signature shows the fold-change of the genes. To the right of the signature, yellow and blue represents the number of publications which showed increased or decreased expression of the gene, with intensity representing the number of individual publications which showed the effect. Green represents genes where there is conflicting information regarding the expression of the gene by the chemical exposure, which could be due in part to lack of annotation of tissue of origin. PB, phenobarbital; Cypro, cyproconazole; Epoxi, epoxiconazole; Flu, fluconazole; Propi, propiconazole; Tri, triadimefon. C. Top canonical pathways enriched for the genes in the CAR biomarker signature. Genes were examined by Ingenuity Pathways Analysis. D. Top transcription factors predicted to regulate the genes in the CAR biomarker signature, as determined by Ingenuity Pathways Analysis.](nrs-13-002-g2){#f2}

The identified signature genes could be either direct transcriptional targets of CAR or indirect targets but still dependent on CAR for altered expression. Many of the genes in the CAR signature are known direct targets of CAR including *Cyp2b10*, *Cyp2c55* and *Gadd45b* ([@r42]; [@r11]). To comprehensively assess whether the genes in the CAR signature were previously identified as being regulated by CAR activators, we used the Comparative Toxicogenomics Database (CTD; <http://ctdbase.org/>) to find published relationships between chemicals and the signature genes in mice. [Figure 2B](#f2){ref-type="fig"} shows the gene-chemical interactions for 2 of the 3 CAR activators (phenobarbital, TCPOBOP) used to construct the signature. In addition, information on gene expression effects of 5 conazole fungicides previously thought to activate CAR were examined. The conazoles are further evaluated for CAR activation (see below). Most of the gene-chemical interactions for the signature genes have been annotated for phenobarbital, TCPOBOP, and propiconazole. Fewer, but generally consistent interactions have been annotated for the other chemicals. Overall, the majority of the CAR signature genes exhibited directional changes consistent with findings in the literature.

The CAR signature genes were evaluated for canonical pathway enrichment by Ingenuity Pathway Analysis (IPA) ([Figure 2C](#f2){ref-type="fig"}). The top 10 pathways enriched with the signature genes included those previously associated with CAR regulation, e.g., Xenobiotic Metabolism Signaling ([@r7]), and included those regulated by AhR (Aryl Hydrocarbon Receptor Signaling) and PXR (PXR/RXR Activation). (It should be noted that the genes in the CAR signature do not include those in either the AhR or PXR signatures developed using similar methods (Oshida et al., in preparation)). Activation of CAR by AhR or PXR activators is discussed below. The upstream analysis function of IPA identified a number of transcription factors that were predicted to regulate the signature genes ([Figure 2D](#f2){ref-type="fig"}). CAR was the top scoring transcription factor (p-value = 1.09E-11). Other transcription factors included PXR (NR1I2), NFE2L2 (Nrf2), POU2F1, PPARA, retinoic acid orphan receptors (RORA, RORC), TP53, PPARGC1A, and the CAR heterodimeric partner, RXRA.

A rank-based strategy to predict CAR activation
-----------------------------------------------

The biomarker signature was compared to gene lists using the Running Fisher's algorithm, resulting in a correlation direction (positive or negative) and an associated p-value of the similarity ([@r23]). Because the Running Fisher's algorithm uses similarity as a metric, it could be hypothesized that biosets that have similarity to each other (based on a low p-value) would exhibit similar gene expression behavior. To visualize the relationships between the Running Fisher's algorithm p-value and the expression of genes in the biomarker signature, 468 biosets of statistically-filtered genes were evaluated for similarity to the CAR biomarker signature and then sorted by p-value. The left of [Figure 3A](#f3){ref-type="fig"} shows that for biosets which had a positive correlation to the biomarker signature, the lower the p-value, the more the bioset appears similar to the biomarker signature, due to similarities in the direction and the relative magnitude of the changes. These biosets include a number of known activators of CAR (phenobarbital and TCPOBOP), as well as perfluorinated compounds (discussed below). The right of the figure shows a smaller group of biosets that exhibited negative correlation to the biomarker signature; the biosets on the far right exhibited the lowest p-value for negative correlation. In general, these biosets exhibit a pattern of gene expression that was opposite to that of the biomarker signature, and included lipopolysaccharide (LPS) and TNFα exposure, as well as various infections. Given that CAR can be suppressed by a number of chemicals (see below), the biosets with negative correlation to the CAR biomarker signature may be hypothesized to reflect CAR suppression.

![The CAR biomarker signature accurately predicts CAR activation.\
A. Heat map showing the expression of genes in the CAR biomarker signature across 468 biosets. Genes in the biomarker signature were ordered based on their average fold-change. Biosets were ordered based on their similarity to the CAR biomarker signature using the p-value of the Running Fisher's test. Biosets with positive correlation are on the left and biosets with negative correlation are on the right. The red vertical lines denote a p-value of 10^-4^. B. Similarity of the CAR biomarker signature to biosets from the three chemicals used to derive the biomarker signature in wild-type but not CAR-null mice. Additional comparisons of mice expressing the human CAR gene (hCAR) expressed in the CAR-null background are shown. All p-values from comparisons of each bioset to the CAR biomarker signature were converted to --log10 values. Those comparisons which exhibited negative correlation to the biomarker signature were given a negative value. C. The CAR biomarker signature correctly identifies three known CAR activators (Aroclor-1260, PCB-153 and phenobarbital) in mice exposed to 12 diverse treatments. Open bars, females. Filled bars, males. Conditions of exposure are found in [Supplementary File 2](#SM1){ref-type="supplementary-material"}. D. Summary of the sensitivity and specificity of the CAR biomarker signature. The biomarker signature was compared to chemicals that were known positives or negatives for CAR activation.](nrs-13-002-g3){#f3}

The ability of the biomarker signature to correctly identify known CAR activators was determined. The biosets from wild-type mice treated with the three compounds used to build the biomarker signature exhibited statistically-significant similarity to the biomarker signature (p-values ≤ 10^-17^), whereas the biosets from the corresponding treated CAR-null mice were not significant ([Figure 3B](#f3){ref-type="fig"}). The species-specificity of the biomarker signature was also examined in this dataset by assessing CAR activation in CAR-null mice expressing a human CAR gene (hCAR mice). Exposure to the human CAR activator CITCO led to the greatest significance compared to the other chemicals, and the significance was approximately equal to that in wild-type mice. Phenobarbital, also known to activate human CAR, resulted in significant CAR activation. In contrast, the mouse-specific activator TCPOBOP did not result in significant CAR activation. In an additional analysis, we show that the CAR biomarker signature can detect CAR activation even at low doses of an inducing compound ([Supplementary File 2](#SM1){ref-type="supplementary-material"}).

The ability of the biomarker signature to distinguish compounds that are known activators of CAR from those that activate other transcription factors was examined. Male and female mice were administered 12 different chemicals or biological agents. These included those that principally activate AhR (2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD), β-naphthoflavone), CAR (Aroclor-1260, PCB-153, phenobarbital), or peroxisome proliferator-activated receptor α (PPARα) (ciprofibrate, WY-14,643 (WY)). Other treatments induce inflammation (LPS, interleukin-6, tumor necrosis factor α (TNFα)) or hypoxia (cobalt, phenylhydrazine). As expected, Arochlor-1260 and phenobarbital activated CAR in males and females ([Figure 3C](#f3){ref-type="fig"}). The third CAR activator, PCB-153, activated CAR in females only. CAR was also activated by AhR activators β-naphthoflavone and TCDD, the PPARα activator WY, and phenylhydrazine, all in females but not males. A number of treatments suppressed CAR including WY in male mice and LPS and TNFα in female mice. An inflammatory state has been shown to suppress CAR activity ([@r5] and discussed below). There is evidence that PPARα and CAR interact to suppress the activity of each other ([@r12]). The activation of CAR by AhR activators is explored further below. Therefore, the biomarker signature correctly identified compounds which activate CAR, as well as some intriguing regulation of CAR by prototypical activators of other transcription factors, sometimes in a sex-dependent manner.

A classification analysis using the Running Fisher's algorithm was performed. The final number of biosets evaluated was 28 positives and 32 negatives. Using a p-value ≤ 10^-4^ as the cutoff, the biomarker signature resulted in 96% sensitivity and a 97% specificity ([Figure 3D](#f3){ref-type="fig"}). These methods were superior to a number of machine learning algorithms (described in [Supplementary File 2](#SM1){ref-type="supplementary-material"}).

Analysis of a mouse liver gene expression compendium
----------------------------------------------------

To find factors that affect activation of CAR, a mouse liver gene expression compendium was constructed and annotated, as detailed in the Methods. The compendium consists of biosets of gene expression changes in the livers of mice, mouse primary hepatocytes, or mouse liver-derived cell lines altered by diverse factors. The compendium contains \~1850 biosets of gene expression changes between control and experimental states including \~470 chemical, \~450 gene, \~220 diet, \~100 hormone or cytokine, \~90 life stage, \~90 stress and \~120 strain comparisons.

Using the Running Fisher's algorithm, the CAR biomarker signature was used for classifying the biosets as inducing, suppressing or having no effect on CAR. A total of 286 biosets were classified as affecting CAR, including 208 activating and 78 suppressing CAR (p-value ≤ 10^-4^). A summary of the bioset factors in which CAR was altered are shown in [Figure 4A](#f4){ref-type="fig"}. The distribution of the biosets indicates that out of all of the factors examined, chemicals and genetic models have the largest effects on CAR. The effects of chemicals on CAR are discussed below. Because of space limitations, the effects of other factors will be described in another publication (Vasani et al., in preparation).

![CAR activation or suppression in a mouse liver compendium.\
A. Assessment of CAR activation or suppression in a mouse liver compendium. A p-value of each of the \~1850 comparisons to the CAR biomarker signature was derived using the Running Fisher's algorithm. All p-values were converted to --log10 values as described in [Figure 3B](#f3){ref-type="fig"}. The number of biosets with a p-value ≤ 10^-4^ for either activation or suppression in the indicated categories are shown. B. Activation or suppression of CAR by chemical exposure. The cutoff values are shown for reference. C. Relationships between *Car* gene expression changes and predictions of CAR activation or suppression. The biosets were divided into those in which *Car* mRNA expression was increased, decreased or exhibited no change. Predictions of the number of biosets for CAR activation or suppression are shown for the three groups.](nrs-13-002-g4){#f4}

The distribution of --log(p-values) across the 461 chemical comparisons representing \~150 chemicals is shown in [Figure 4B](#f4){ref-type="fig"} and shows that 144 of the chemical treatments significantly activated CAR and 15 significantly suppressed CAR.

A number of mechanisms may determine how chemical exposure affects CAR-regulated biomarker signature genes. Because CAR exhibits constitutive activity, one mechanism of activation could involve increases in the expression of the *Car* gene and protein. The relationship between expression of the *Car* gene and the biomarker signature predictions was determined ([Figure 4C](#f4){ref-type="fig"}). *Car* expression was derived using the statistically-filtered gene lists from the same microarray experiments used to determine CAR activation status. The biosets were divided into those in which *Car* gene expression was increased, decreased or exhibited no change. For those biosets in which *Car* expression significantly increased (fold change ≥ 1.2), there were 129 biosets which exhibited no significant CAR activation or suppression (p-value \> 10^-4^) (not shown), 49 biosets in which CAR was activated and only 6 biosets in which CAR was suppressed. For those biosets in which *Car* expression was decreased, there were 169 biosets which exhibited no significant CAR activation or suppression (p-value \> 10^-4^) (not shown), 11 biosets in which CAR was activated and 27 biosets in which CAR was suppressed. For those biosets in which there was no change in *Car* expression, there were 157 and 47 biosets that exhibited activation or suppression of CAR, respectively. Therefore, *Car* gene expression does not appear to be tightly correlated with CAR activation or suppression and is not a reliable predictor of CAR activation status.

Crosstalk between CAR and other signaling pathways: activation of CAR by AhR activators
---------------------------------------------------------------------------------------

Results from our 12-treatment classification experiment (above) indicated that TCDD and β-naphthoflavone exposure leads to CAR activation. CAR activation was evaluated in other experiments in which intact mice or mouse primary hepatocytes were exposed to AhR activators. CAR was activated in wild-type but not AhR-null mice exposed to 1 mg/kg of TCDD for 19 hrs (from study GSE10082) ([Figure 5A](#f5){ref-type="fig"}, left). TCDD consistently increased CAR activation at two doses for 24 hrs in three strains of mice (from E-MEXP-1231) ([Figure 5A](#f5){ref-type="fig"}, right).

![Activation of CAR by AhR activators.\
A. Activation of CAR by TCDD. Activation of CAR by TCDD in two studies in which transcriptional effects were examined. (Left) Wild-type and AhR-null mice were exposed to 1 mg/kg of TCDD for 19 hrs (from study GSE10082). (Right) Three strains of mice were exposed to two dose levels of TCDD (from E-MEXP-1231). B. Activation of CAR by benzo\[a\]pyrene (B\[a\]P) in three studies in which transcriptional effects were examined. (Left) The Hepa1c1c7 and AhR-null Hepa1c1c7 cell lines were exposed to 5 μM B\[a\]P for 8 hrs (from study GSE11796). (Middle) Primary hepatocytes from wild-type or Xpa1/p53-null mice were exposed to four dose levels of B\[a\]P for 24 hrs (from study E-TABM-1139). (Right) Hepatocytes from wild-type mice were dosed with 30 μM of B\[a\]P (from E-MEXP-2209).](nrs-13-002-g5){#f5}

Effects of the AhR activator benzo\[a\]pyrene (B\[a\]P) on CAR activation were also examined. CAR activation by B\[a\]P approached significance (p-value = 3E-4) when the Hepa1c1c7 cell line was exposed to 5 μM B\[a\]P for 8 hrs, whereas B\[a\]P in AhR-null Hepa1c1c7 hepatocytes had no effect on the CAR biomarker signature (from study GSE11796) ([Figure 5B](#f5){ref-type="fig"}, left). CAR activation was observed at 60 μM but not three lower doses in primary hepatocytes from wild-type mice treated for 24 hrs (study E-TABM-1139). In parallel experiments from the same study, hepatocytes treated with B\[a\]P from Xpa1/p53-null mice exhibited CAR activation for most of the treatments ([Figure 5B](#f5){ref-type="fig"}, middle). In a time course experiment in wild-type hepatocytes dosed with 30 μM of B\[a\]P (from E-MEXP-2209) ([Figure 5B](#f5){ref-type="fig"}, right), CAR was activated at 12 hrs but not significantly at 24 or 36 hrs. It should be noted that under the conditions of exposure for these experiments with AhR activators, AhR was strongly activated based on large inductions of the AhR target genes *Cyp1a1* and *Cyp1a2* (data not shown).

The effect of TCDD on CAR marker genes was evaluated and the results are consistent with TCDD activating CAR marker genes in a CAR-dependent manner ([Supplementary File 2](#SM1){ref-type="supplementary-material"}). [@r32] found that exposure to the AhR activator β-naphthoflavone can lead to increases in *Car* gene expression levels as the basis for the activation of a number of CAR-regulated genes in mouse liver. A minor increase in *Cyp2b10* in response to TCDD in male WT mice, but not AhR-null mice, was noted previously ([@r1]). Taken together, our work confirms and extends these observations to support the hypothesis that exposure to at least three AhR activators (TCDD, β-naphthoflavone, and B\[a\]P) leads to activation of CAR.

Crosstalk between CAR and other signaling pathways: activation of CAR by PXR activators
---------------------------------------------------------------------------------------

Given the extensive evidence of overlapping functions in regulating xenobiotic metabolism and transport by CAR and PXR ([@r7]), the effects of PXR activator exposure on CAR activation were examined. Wild-type and PXR-null mice were administered the PXR activator, pregnenolone-16-α-carbonitrile (PCN) for 4 days and global gene expression was examined (Methods). CAR was significantly activated by PCN in wild-type mice ([Figure 6](#f6){ref-type="fig"}, left). In the PXR-null mice, the significance of the activation of CAR was diminished but not abolished compared to wild-type mice. In a similar study (GSE23780), wild-type and PXR-null mice were administered the β-secretase inhibitor "Compound 13" for 4 days. CAR was significantly activated in wild-type but not PXR-null mice. The expression of *Cyp2b10* and *Akr1b7* was examined in the livers of PCN-treated mice ([Figure 6](#f6){ref-type="fig"}, right). PCN caused increases in both genes in wild-type mice. Although the activation was still significant from controls in PXR-null mice, the level of activation was significantly less than that in treated wild-type mice. Overall, these results indicate that activation of CAR by PXR activators was partially or completely PXR-dependent.

![Effect of PXR activators on CAR activation.\
(Left) Activation of CAR by PXR activators is diminished or abolished in PXR-null mice (from this study and GSE23780). Wild-type or PXR-null mice were treated each day with pregnenolone-16-α-carbonitrile (PCN, 400 mg/kg) or compound 13 (C13, 150 mg/kg) for 4 days. (Right) Activation of CAR marker genes by PCN in wild-type and PXR-null mice. \*Significant from corresponding control at p-value ≤ 0.05; \*\*Significant from corresponding control at p-value ≤ 0.01; ^\#^significant between wild-type and nullizygous comparisons at p-value ≤ 0.05; ^\#\#^significant between wild-type and nullizygous comparisons at p-value ≤ 0.01.](nrs-13-002-g6){#f6}

Suppression of CAR activation by chemical exposure
--------------------------------------------------

Compounds were identified that suppressed constitutive CAR activation. Acetaminophen (APAP) is known to be metabolized by CAR-regulated enzymes to toxic metabolites; CAR-null mice are resistant to APAP toxicity ([@r49]). APAP suppressed CAR in a strain- and time-dependent manner, with the most significant suppression being in the C57 and DBA strains at 6 hrs of exposure (from [@r25]) ([Figure 7A](#f7){ref-type="fig"}). The pattern of CAR suppression did not parallel strain susceptibility to APAP (C57 \> SMJ \>DBA \> SJL). Two of the 9 biosets from mice exposed to lipopolysaccharide (LPS) showed suppression of CAR, with 3 of the other biosets approaching significance for suppression ([Figure 7B](#f7){ref-type="fig"}). Concanavalin A, after a 6 hr exposure but not 1 or 3 hr exposure, led to suppression of CAR ([Figure 7C](#f7){ref-type="fig"}). Lastly, a study in which mice were exposed to different sized silicon dioxide particles for 6 hrs showed that 300 nm particles caused suppression of CAR; exposure to the smaller-sized nanoparticles approached significance ([Figure 7D](#f7){ref-type="fig"}). All of the treatments that suppressed CAR resulted in increases in inflammatory mediators, indirectly assessed by examination of the expression of two genes, the AP-1 subunit, *Jun* and the NF-kB subunit, *Rela,* both known to be increased under inflammatory conditions ([Figure 7A-D](#f7){ref-type="fig"}). A number of previous studies have shown that inflammatory signaling leads to suppression of *Car* gene expression (Assanat et al., 2004; [@r6]). Except for LPS exposure, most of the conditions in which CAR was suppressed also exhibited decreases in *Car* gene expression ([Figure 7A-D](#f7){ref-type="fig"}). Overall, the data add to the evidence that compounds that induce inflammatory responses in the liver negatively regulate CAR, consistent with the long-standing observation that inflammation suppresses xenobiotic metabolism ([@r27]).

![Chemical suppression of CAR.\
Predictions of CAR activation/suppression were compared to the expression of the *Car* gene and expression of two markers of inflammatory responses, *Rela* and *Jun* (derived from the same microarray experiments). A. Suppression by acetaminophen. Effects of acetaminophen treatment were examined at either 3 or 6 hrs of exposure in four strains of mice from [@r25] study. B. Suppression by lipopolysaccharide exposure. The study from which the bioset was derived is indicated by the GEO number. One study is not archived in GEO. C. Suppression of CAR by concanavalin A. Balb/c mice were injected with 20 mg/kg concanavalin A and sacrificed at the indicated times (from GSE17184). D. Suppression of CAR by 300 nm silicon dioxide particles. Mice were given intravenous injections of the indicated doses of the various sized silicon dioxide nanoparticles and then sacrificed at 6 hrs (from GSE30861).](nrs-13-002-g7){#f7}

Conazole pesticides activate CAR
--------------------------------

CAR activation by anti-fungal conazole pesticides has been hypothesized to be part of the mechanistic process leading to liver cancer ([@r30]). However, except for cyproconazole ([@r33]), direct evidence that CAR mediates conazole effects is lacking. Biosets from wild-type mice treated with 5 conazoles were evaluated for CAR activation. [Figure 8A](#f8){ref-type="fig"} shows that with increasing dose and time of exposure, there was usually increasing significance of the similarity to the CAR biomarker signature for cyproconazole, epoxiconazole, myclobutanil, propiconazole, and triadimefon biosets.

![Conazole fungicides activate CAR.\
A. Effects of exposure to 5 conazoles on CAR activation. Biosets were derived from [@r46] (for Myclo, Propi, and Triad) or [@r18] (for Cypro and Epoxi) studies. Abbreviations: Cypro, cyproconazole; Epoxi, epoxiconazole; Myclo, myclobutanil; Propi, propiconazole; Triad, triadimefon. B. Liver to body weight ratios of wild-type and CAR-null mice given propiconazole (210 mg/kg) or triadimefon (165 mg/kg) for 7 days. \*\*Significant from corresponding control at p-value ≤ 0.01. C. Hepatocyte proliferation in wild-type and CAR-null mice exposed to propiconazole for 7 days. Hepatocyte proliferation was evaluated as detailed in the Methods. \*Significant from corresponding control at p-value ≤ 0.05. D. Expression of marker genes for CAR and PXR in the livers of wild-type and CAR-null mice given propiconazole or triadimefon for 7 days. \*\*significant from corresponding control at p-value ≤ 0.01; ^\#\#^significant between wild-type and nullizygous comparisons at p-value ≤ 0.01.](nrs-13-002-g8){#f8}

To directly determine whether CAR is involved in conazole-mediated effects, wild-type and CAR-null mice were exposed to propiconazole or triadimefon for 7 days by gavage, as described in the Methods. Liver to body weight ratios were increased in wild-type mice for each compound ([Figure 8B](#f8){ref-type="fig"}). The increases were also observed in CAR-null mice exposed to triadimefon, but not in CAR-null mice exposed to propiconazole. The labeling index was increased in hepatocytes from wild-type but not CAR-null mice exposed to propiconazole ([Figure 8C](#f8){ref-type="fig"}). (Triadimefon was not tested for cell proliferation effects.)

Marker genes were examined for expression changes after exposure ([Figure 8D](#f8){ref-type="fig"}). *Cyp2b10* was increased by propiconazole and triadimefon, and the increases were dependent on CAR, as they were no longer significantly altered in CAR-null mice. Other genes that were markers of CAR or PXR were examined. *Birc5*, found to be regulated by PXR and part of a PXR biomarker signature (Oshida et al., in preparation), as well as *Cyp3a11*, a prototypical marker gene for PXR, were activated by propiconazole and triadimefon in wild-type and CAR-null mice, consistent with a CAR-independent mechanism. The protein encoded by *Cyp51* is inhibited by conazoles in fungi ([@r44]). *Cyp51* and *Gstm3* were increased in both wild-type and CAR-null mice, with significantly higher increases for *Gstm3* in Car-null mice after exposure to both compounds. *Gsta2* was induced by propiconazole and triadimefon in wild-type mice and by propiconazole in CAR-null mice.

In summary, the biomarker signature identified multiple time-dose combinations that led to CAR activation by all 5 of the tested conazoles using microarray profiles. In our study of wild-type and CAR-null mice, propiconazole exhibited CAR-dependent effects including increases in liver to body weight, increases in hepatocyte proliferation and increases in *Cyp2b10*. CAR-dependent transcriptional effects were noted for triadimefon including induction of *Cyp2b10* and *Gsta2*. As propiconazole and triadimefon increase liver tumors in mice ([@r2] and references therein), the adverse outcome pathways that lead to liver cancer for propiconazole and triadimefon are likely different, and may include a CAR AOP for propiconazole.

Perfluorinated compounds activate CAR, but CAR is not required for growth effects by PFOA
-----------------------------------------------------------------------------------------

The perfluorinated surfactant chemicals are environmentally-relevant compounds that appear to mediate most of their effects in the liver through the PPARα nuclear receptor ([@r12]). Previous studies with PFOA and PFOS identified a subset of genes regulated by these compounds that were PPARα-independent and hypothesized to be regulated by CAR activation ([@r36], [@r37]). However, direct evidence for CAR activation is lacking.

The ability of four perfluorinated compounds and other PPARα activators to activate CAR was examined in wild-type and PPARα-null mice. The hypolipidemic compounds, fenofibrate and WY, given for 6 hrs (GSE8396), activated CAR in wild-type but not PPARα-null mice ([Figure 9A](#f9){ref-type="fig"}). Di-(2-ethylhexyl)phthalate (DEHP) given to wild-type mice for up to 72 hrs was also a CAR activator (from GSE55733, data not shown), supporting earlier studies in which DEHP effects were compared between wild-type and CAR-null mice ([@r35]). Not all compounds that activated PPARα were CAR activators, as three piperidine-derived PPARα activators did not activate CAR (from GSE12147, data not shown). The effects of exposure on CAR activation was examined for perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) from published studies (GSE22871 and GSE9786) and perfluorononanoic acid (PFNA) and perfluorohexanesulfonic acid (PFHxS), which were evaluated in additional experiments, as detailed in the Methods. All four compounds activated CAR in wild-type mice, and the activation of CAR was generally more significant in PPARα-null mice ([Figure 9A](#f9){ref-type="fig"}), consistent with previous findings showing increased expression of CAR marker genes by PPARα activators in PPARα-null mice compared to wild-type mice (summarized in [@r12]).

![Perfluorinated compounds activate CAR in a PPARα-independent manner.\
A. Effect of exposure to PPARα activators in wild-type and PPARα-null mice on CAR activation. The indicated dose levels are shown. For GSE8396, mice were given one 400uL injection of a 10mg/mL solution of either fenofibrate or WY in 0.5% carboxymethyl cellulose (CMC) or 400 μl of 0.5% CMC only. Abbreviations: Feno, fenofibrate; PFHxS, perfluorohexane sulfonate; PFNA, perfluoronanoic acid; PFOS, perfluorooctane sulfonate; PFOA, perfluorooctanic acid. B. Effects of WY-14,643, PFNA and AGN194,204 on activation of CAR marker genes in wild-type and PPARα-null mice. \*Significant from corresponding control at p-value ≤ 0.05; \*\*Significant from corresponding control at p-value ≤ 0.01. C. Liver to body weights of wild-type and CAR-null mice given PFOA or PFOS for 7 days. \*\*Significant from corresponding control at p-value ≤ 0.01. D. Hepatocyte proliferation in wild-type and CAR-null mice exposed to PFOA for 7 days. Hepatocyte proliferation was evaluated as detailed in the Methods. \*\*Significant from corresponding control at p-value ≤ 0.01. E. Expression of marker genes for PPARα, CAR and PXR in the livers of wild-type and CAR-null mice given PFOA for 7 days. \*Significant from corresponding control at p-value ≤ 0.05; \*\*Significant from corresponding control at p-value ≤ 0.01; ^\#^significant between wild-type and nullizygous comparisons at p-value ≤ 0.05; ^\#\#^significant between wild-type and nullizygous comparisons at p-value ≤ 0.01. F. Expression of marker genes for PPARα, CAR and PXR in the livers of wild-type and CAR-null mice given PFOS for 7 days. \*Significant from corresponding control at p-value ≤ 0.05; \*\*Significant from corresponding control at p-value ≤ 0.01. ^\#^Significant from corresponding control at p-value ≤ 0.05; ^\#\#^significant from corresponding control at p-value ≤ 0.01.](nrs-13-002-g9){#f9}

Three structurally-diverse PPARα activators were examined for effects on CAR-regulated genes. There was no activation of *Cyp2b10* or *Akr1b7* in livers of mice treated with WY for 3 days ([Figure 9B](#f9){ref-type="fig"}, left), consistent with the lack of significant CAR activation by WY given for 5 days in wild-type or PPARα-null mice (from GSE8295, data not shown). Examination of the expression of CAR target genes showed minimal increases in expression of *Cyp2b10* and *Akr1b7* in wild-type mice treated with PFNA (3 mg/kg), but greater increases in the treated PPARα-null mice ([Figure 9B](#f9){ref-type="fig"}, middle). Gene expression was examined in wild-type and PPARα-null mice after exposure to the panRXR agonist (AGN194,204), which activates nuclear receptor-RXR heterodimers through RXR activation. Treatment with AGN resulted in activation of *Akr1b7* but not *Cyp2b10* in wild-type and PPARα-null mice ([Figure 9B](#f9){ref-type="fig"}, right). The results are consistent with the predictions of CAR activation for PFNA and weak or no activation of CAR by WY. The results also indicate that AGN regulates only a subset of CAR-regulated genes in a PPARα-independent manner.

To directly determine the role of CAR in mediating the effects of PFOA and PFOS, these compounds were given by gavage to wild-type and CAR-null mice each day for 7 days, as detailed in the Methods. Increases in liver to body weights were observed in both wild-type and CAR-null mice that were not significantly different between strains ([Figure 9C](#f9){ref-type="fig"}). PFOA increased hepatocyte proliferation that was also not significantly different between strains ([Figure 9D](#f9){ref-type="fig"}). (PFOS was not evaluated for cell proliferation effects.) A number of marker genes for PPARα, CAR and PXR were examined after PFOA exposure in wild-type and CAR-null mice ([Figure 9E](#f9){ref-type="fig"}). Marker genes for PPARα (*Acox1, Cyp4a10*) were increased in both strains of mice. Increases in *Cyp2b10* observed in wild-type mice were abolished in CAR-null mice. Increases in *Birc5* were partially dependent on CAR. A number of genes were induced in both strains to various extents, with the increases being significant in wild-type mice only (*Cyp3a13*), CAR-null mice only (*Gstm3*, *Cyp3a11*), or both strains (*Gsta2*). Gene expression was also examined after PFOS exposure ([Figure 9F](#f9){ref-type="fig"}). The induction of *Acox1* and *Cyp4a10* were muted compared to PFOA, with marginal induction of *Acox1* only becoming significant in CAR-null mice and induction of *Cyp4a10* only significant in wild-type mice. The induction of *Cyp2b10* and *Gstm3* were clearly CAR-dependent. Inductions of the other genes were significant in wild-type (*Cyp3a11*) or CAR-null (*Cyp3a11, Gsta2*) mice. Another perfluorinated compound, perfluorodecanoic acid exposure, was shown to require CAR but not PPARα for induction of *Cyp2b10* ([@r9]). Taken together with a large number of published studies (summarized in [@r12]), PPARα plays a dominant role in mediating the effects of PFOA and PFOS in the mouse liver, including effects on liver to body weights, hepatocyte proliferation, and gene expression. Although we present direct evidence that the perfluorinated compounds activate CAR, the activation of CAR likely plays a subordinate role to PPARα in mediating the adverse effects of these compounds, including the induction of liver cancer.

Discussion
==========

A biomarker signature-based approach was used to identify chemicals that activate or suppress CAR. To create the CAR biomarker signature, a unique microarray study was utilized in which wild-type and CAR-null mice were exposed to three structurally-diverse CAR activators. Genes that were consistently activated or repressed in a CAR-dependent manner were identified using a stringent set of criteria, including 9 statistical tests and a number of filters, ultimately resulting in a final list of 128 probe sets representing 83 genes. To screen for factors that led to alterations of CAR, we compared the biomarker signature to a gene expression database of annotated biosets using the fold-change rank-based nonparametric Running Fisher's algorithm ([@r23]), analogous to the Gene Set Enrichment Analysis (GSEA) method ([@r24]; [@r40]). The biomarker signature reliably predicted CAR activation. Our test to assess predictive capability gave a balanced accuracy of 97% ([Figure 3E](#f3){ref-type="fig"}), far superior to predictions using a number of well-known machine learning classification algorithms ([Supplementary File 2](#SM1){ref-type="supplementary-material"}). Additionally, the biomarker signature was able to distinguish between chemical activators of CAR and other xenobiotic-activated transcription factors ([Figure 3D](#f3){ref-type="fig"}). Therefore, the CAR biomarker signature coupled with the Running Fisher's algorithm will be a useful strategy for predicting CAR effects in future genomic studies. The set of genes in the biomarker signature is a useful starting point for identifying a smaller subset of genes that can reliably predict effects on CAR in high-throughput screens of environmentally-relevant chemicals or drugs.

Comparison of the CAR biomarker signature to biosets in a gene expression compendium identified diverse factors that when perturbed, resulted in effects on CAR ([Figure 4A](#f4){ref-type="fig"}). Consistent with CAR serving as a promiscuous target for diverse drugs and chemicals, about two-thirds of the biosets in the compendium that activated CAR were from chemical exposure. Other factors, including knockout or overexpression of genes in the liver, did have effects on CAR, and will be described in future reports. Activation of CAR through direct binding, typified by CITCO and TCPOBOP, is one mechanism by which CAR is activated ([Figure 10A](#f10){ref-type="fig"}). CAR is also activated indirectly by a number of compounds, with the best characterized being phenobarbital. In the absence of phenobarbital exposure, a key residue on CAR (Thr^38^) is phosphorylated, resulting in sequestration of CAR in the cytoplasm. Blocking EGFR activity by interaction with phenobarbital results in dephosphorylation of Thr^38^ by protein phosphatase 2A, nuclear translocalization of CAR and regulation of gene expression ([@r29]). Our methods for assessing chemical-induced CAR activation, like typical *in vitro* trans-activation techniques, cannot distinguish between direct or indirect activation of CAR. However, the downstream consequences appear to be similar, if not identical, including alteration of xenobiotic metabolism genes and increases in hepatocyte proliferation. Long term exposure to direct (TCPOBOP) or indirect (phenobarbital) CAR activators leads to increases in liver cancer in mice that are both dependent on CAR (discussed in [@r14]).

![Chemical activation or suppression of CAR.\
A. Chemicals which lead to activation of CAR. B. Chemicals which lead to suppression of CAR.](nrs-13-002-g10){#f10}

Our biomarker signature-based approach for chemical screening led to a number of novel observations. First, chemicals were identified that highlight the cross-talk with other signaling pathways regulated by xenobiotic-activated receptors. These included two activators of AhR (TCDD and B\[a\]P) that activate CAR in an AhR-dependent manner ([Figure 5A-C](#f5){ref-type="fig"}). Compound 13 and PCN activate CAR at least partly through a PXR-dependent mechanism ([Figure 6](#f6){ref-type="fig"}). In contrast, a number of PPARα activators activate CAR independent of PPARα ([Figure 9A](#f9){ref-type="fig"}). The fact that AhR and PXR activators (but not PPARα activators) require their receptors for CAR activation, leads to the hypothesis that the activation of CAR requires a factor(s) that is dependent on prior activation of AhR or PXR.

Second, compounds were identified that negatively regulate CAR, including acetaminophen, LPS, concanavalin A, and 300 nm silicon dioxide particles ([Figure 10B](#f10){ref-type="fig"}). These chemicals are all known to cause a cascade of effects to varying degrees, including increases in liver injury, infiltration of inflammatory cells, secretion of cytokines and induction of inflammatory mediators. Suppression of CAR may be through decreases in *Car* gene expression, as decreases in expression of the *Car* gene paralleled CAR suppression, even though the *Car* gene was not part of the CAR biomarker signature ([Figure 7](#f7){ref-type="fig"}). Glucocorticoid receptor (GR) regulates the basal expression of the *Car* gene, and under conditions of inflammation, the NF-kB subunit RelA interacts with and prevents GR from activating *Car* ([@r5]). Even though decreases in *Car* gene expression do not consistently lead to decreases in CAR activation ([Figure 4C](#f4){ref-type="fig"}), exposure to LPS, ConA or 300 nm silicon dioxide particles showed a close association between induction of *Rela* and *Jun*, CAR suppression, and decreases in the expression of the *Car* gene.

Lastly, we followed up on our biomarker signature-based screening to determine dependency on CAR of effects of members of the environmentally-relevant chemical classes conazoles and perfluorinated compounds. The studies showed that effects of propiconazole linked to liver cancer (increases in liver weight and hepatocyte proliferation) are CAR-dependent ([Figure 8](#f8){ref-type="fig"}), and support the hypothesis that propiconazole induces liver cancer by a complex mechanism that includes a CAR-dependent event ([@r30]). The other conazole examined, triadimefon, may cause liver effects via an alternative AOP(s). PFOA and PFOS, while clearly activating *Cyp2b10* in a CAR-dependent manner, exhibited increases in cell proliferation and/or liver weight that were CAR-independent ([Figure 9](#f9){ref-type="fig"}). Linkage of CAR activation in these studies to CAR-dependent induction of liver tumors would require a comprehensive assessment of the long-term effects of chemical exposure in wild-type and CAR-null mice.

The methods described here for identifying factors that affect CAR will be a useful strategy for identification of CAR modulators in future genomic studies. Because there are likely a minor number of CAR gene targets that exhibit similar regulation across tissues and species ([@r26]), reliable biomarker signatures that predict CAR activation might have to be built using treated and control samples from the tissue and species of interest. For example, a human CAR biomarker signature might be built using microarray data before and after exposure to CAR activators in wild-type cells which exhibit appropriate expression of hCAR compared to those in which hCAR has been knocked down using shRNA technologies.
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